



**About:** EnzySurge specializes in producing and providing proprietary and innovative solutions to promote fast wound and burn healing.

**Industry:** Medical - Chronic wounds, burn injuries, Diabetes foot ulcers, pressure ulcers, veterinarian wound care

**Stage:** Post revenues

**Market Size:** +\$15B

**Employees:** 11

**Patents:** Registered patents in the US, EU, IL, Japan, China, Russia, India and S. Africa.

**Funding To-Date:** \$17M

**Required Funding:** \$5M

**Use of Proceeds:**

- Expand market share in existing markets
- Expand to the Chinese & additional markets
- Obtain regulatory approvals for products in the pipeline



## Products

EnzySurge has developed two products, both commercially marketed globally:

1. **SilverStream®** - a patented wound management solution, combining a low concentration of silver ions, menthol and glycerol plus a surfactant, dissolved in a hypertonic solution.
2. **SilVet™** - Identical to SilverStream; used to treat all types of wounds and burns in animals.

## Clinical Efficacy

Over 50,000 patients were treated with SilverStream with excellent results, observed in elimination of infection, reducing pain and bad odor, expediting wound healing process, avoiding amputations and saving patients' lives. SilverStream showed complete safe profile during the treatments, with no serious adverse reaction event observed.

Parameter	Control (Povidone Iodine)	Study (SilverStream)
Granulation tissue on 14th day	82%	95%
Skin graft uptake rate	80%	94%
Hospital stay	35 days	25 days
Positive pus culture	12 patients	6 patients

## Products in the Pipeline

### 1. SilverStream Hydrogel

- An complimentary product to SilverStream for treating chronic wounds and burns, that comes in the form of hydrogel instead of liquid
- Fully reimbursed by US health insurance organizations
- The technical file has been submitted to the US FDA, via 510(k) path (as a Medical Device class II) at the beginning of June 2018

### 2. EnzyStream

- An enzymatic solution preparation, based on the enzyme Papain. It is intended to treat chronic wounds by debridement of non-viable and slough tissue
- Treats lower extremity chronic preliminary venous ulcers
- Completed P1/2a clinical trial

## Management Team

### Moshe Landsberg, CEO

20 years of executive level experience in the development, manufacture and commercialization of bio-pharm and medical products. Former VP Technology & QA at BioCancell Therapeutics and COO at BioPreventative.

### Noa Hadar (PhD), R&D Manager

Holds BSc in Biotechnology and Chemical Engineering, MSc in Biotechnology and PhD in Nano Biotechnology. 12 years of experience in R&D in the fields of Bio Catalysis, Bio-chemistry, Nano Biotechnology and wound healing.

### Gad Bar Sela, VP Marketing & Sales

Holds M.Sc in Organic Chemistry from the Weizmann Institute in Israel; Former VP Marketing & Sales at CommonSense with over 30 years of experience.